Compare $NXTC vs $RNAZ | Chartloom

Compare

$NXTC vs $RNAZ

NextCure Inc · Transcode Therapeutics Inc

NXTC

NextCure Inc

RNAZ

Transcode Therapeutics Inc

Compare $NXTC vs $RNAZ

Comparing NextCure Inc and Transcode Therapeutics Inc

NXTCNextCure Inc

RNAZTranscode Therapeutics Inc

NXTCNextCure Inc

Market cap

$29M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-45.9%

52W performance

4.8%

FCF yield

-126.6%

RNAZTranscode Therapeutics Inc

Market cap

$2M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.9%

52W performance

-82.4%

FCF yield

-1146.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NXTC

RNAZ

Detailed metrics comparison

NXTC

NextCure Inc

RNAZ

Transcode Therapeutics Inc

Market Cap

NXTC$29M

RNAZ$2M

Enterprise Value

NXTC$14M

RNAZ$-6M

Price

NXTC$7.18

RNAZ$1.86

P/E Ratio

NXTCN/A

RNAZN/A

P/S Ratio

NXTC0.85x

RNAZ0.00x

EV/Sales

NXTC0.29x

RNAZ0.00x

EV/EBITDA

NXTC0.00x

RNAZ0.00x

P/B Ratio

NXTC1.92x

RNAZ0.19x

P/FCF Ratio

NXTCN/A

RNAZN/A

EV/FCF

NXTC-0.38x

RNAZ0.25x

PEG Ratio

NXTCN/A

RNAZN/A

Forward P/E (NTM)

NXTCN/A

RNAZN/A

Forward P/S (NTM)

NXTCN/A

RNAZN/A

Revenue (TTM)

NXTC$0

RNAZ$0

Revenue Growth (YoY)

NXTCN/A

RNAZN/A

Forward Rev Growth

NXTC0.0%

RNAZ0.0%

Gross Margin (TTM)

NXTC0.0%

RNAZ0.0%

Operating Margin (TTM)

NXTC0.0%

RNAZ0.0%

EBITDA Margin (TTM)

NXTC0.0%

RNAZ0.0%

Net Margin (TTM)

NXTC0.0%

RNAZ0.0%

FCF Margin (TTM)

NXTCN/A

RNAZN/A

Net Income (TTM)

NXTC$-43M

RNAZ$-46M

FCF (TTM)

NXTC$-37M

RNAZ$-23M

EPS (TTM)

NXTC-$8.05

RNAZ-$48.35

ROE (TTM)

NXTC-17546.0%

RNAZ-3928.0%

ROA (TTM)

NXTC-11370.0%

RNAZ-3601.0%

ROIC (TTM)

NXTC-17546.0%

RNAZ-3922.0%

Cash

NXTC$15M

RNAZ$8M

Debt

NXTC$0

RNAZ$652K

Net Cash/Debt

NXTC$15M

RNAZ$8M

Current Ratio (TTM)

NXTC3.47x

RNAZ1.97x

Quick Ratio (TTM)

NXTC3.13x

RNAZ1.55x

Debt/Equity (TTM)

NXTC0.00x

RNAZ0.00x

Debt/Assets (TTM)

NXTC0.0%

RNAZ0.0%

Interest Coverage (TTM)

NXTCN/A

RNAZN/A

Net Debt/EBITDA (TTM)

NXTC0.00x

RNAZ0.00x

Beta

NXTC1.29

RNAZ1.29

52W Performance

NXTC4.8%

RNAZ-82.4%

YTD Performance

NXTC-45.9%

RNAZ-74.9%

% from 52W High

NXTC-54.4%

RNAZ-91.1%

% from 52W Low

NXTC363.2%

RNAZ22.4%

Asset Turnover (TTM)

NXTC0.10x

RNAZ0.00x

FCF Yield (TTM)

NXTC-126.6%

RNAZ-1146.9%

Earnings Yield (TTM)

NXTC-146.3%

RNAZ-2347.6%

Dividend Yield (TTM)

NXTCN/A

RNAZN/A

Rule of 40

NXTC0.0

RNAZ0.0

EV/GP/RG

NXTCN/A

RNAZN/A

Ticker research

View NXTC research View RNAZ research

Metric	NXTC NextCure Inc	RNAZ Transcode Therapeutics Inc
Market & Valuation
Market Cap	$29M	$2M
Enterprise Value	$14M	$-6M
Price	$7.18	$1.86
P/E Ratio	N/A	N/A
P/S Ratio	0.85x	0.00x
EV/Sales	0.29x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.92x	0.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.38x	0.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-43M	$-46M
FCF (TTM)	$-37M	$-23M
EPS (TTM)	-$8.05	-$48.35
ROE (TTM)	-17546.0%	-3928.0%
ROA (TTM)	-11370.0%	-3601.0%
ROIC (TTM)	-17546.0%	-3922.0%
Financial Health
Cash	$15M	$8M
Debt	$0	$652K
Net Cash/Debt	$15M	$8M
Current Ratio (TTM)	3.47x	1.97x
Quick Ratio (TTM)	3.13x	1.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.29	1.29
52W Performance	4.8%	-82.4%
YTD Performance	-45.9%	-74.9%
% from 52W High	-54.4%	-91.1%
% from 52W Low	363.2%	22.4%
Efficiency & Yields
Asset Turnover (TTM)	0.10x	0.00x
FCF Yield (TTM)	-126.6%	-1146.9%
Earnings Yield (TTM)	-146.3%	-2347.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NXTC research	View RNAZ research

Valuation

P/S Ratio

RNAZ

0.00x

NXTC

0.85x

EV/FCF

NXTC

-0.38x

RNAZ

0.25x

Growth & revenue

Forward Revenue Growth

NXTC

0.0%

RNAZ

0.0%

Profitability & performance

Gross Margin

NXTC

0.0%

RNAZ

0.0%

ROE

RNAZ

-3928.0%

NXTC

-17546.0%

FCF Yield %

NXTC

-126.6%

RNAZ

-1146.9%

52-Week Performance

NXTC

4.8%

RNAZ

-82.4%

Detailed metrics comparison

NXTC

NextCure Inc

RNAZ

Transcode Therapeutics Inc

Market Cap

NXTC$29M

RNAZ$2M

Enterprise Value

NXTC$14M

RNAZ$-6M

Price

NXTC$7.18

RNAZ$1.86

P/E Ratio

NXTCN/A

RNAZN/A

P/S Ratio

NXTC0.85x

RNAZ0.00x

EV/Sales

NXTC0.29x

RNAZ0.00x

EV/EBITDA

NXTC0.00x

RNAZ0.00x

P/B Ratio

NXTC1.92x

RNAZ0.19x

P/FCF Ratio

NXTCN/A

RNAZN/A

EV/FCF

NXTC-0.38x

RNAZ0.25x

PEG Ratio

NXTCN/A

RNAZN/A

Forward P/E (NTM)

NXTCN/A

RNAZN/A

Forward P/S (NTM)

NXTCN/A

RNAZN/A

Revenue (TTM)

NXTC$0

RNAZ$0

Revenue Growth (YoY)

NXTCN/A

RNAZN/A

Forward Rev Growth

NXTC0.0%

RNAZ0.0%

Gross Margin (TTM)

NXTC0.0%

RNAZ0.0%

Operating Margin (TTM)

NXTC0.0%

RNAZ0.0%

EBITDA Margin (TTM)

NXTC0.0%

RNAZ0.0%

Net Margin (TTM)

NXTC0.0%

RNAZ0.0%

FCF Margin (TTM)

NXTCN/A

RNAZN/A

Net Income (TTM)

NXTC$-43M

RNAZ$-46M

FCF (TTM)

NXTC$-37M

RNAZ$-23M

EPS (TTM)

NXTC-$8.05

RNAZ-$48.35

ROE (TTM)

NXTC-17546.0%

RNAZ-3928.0%

ROA (TTM)

NXTC-11370.0%

RNAZ-3601.0%

ROIC (TTM)

NXTC-17546.0%

RNAZ-3922.0%

Cash

NXTC$15M

RNAZ$8M

Debt

NXTC$0

RNAZ$652K

Net Cash/Debt

NXTC$15M

RNAZ$8M

Current Ratio (TTM)

NXTC3.47x

RNAZ1.97x

Quick Ratio (TTM)

NXTC3.13x

RNAZ1.55x

Debt/Equity (TTM)

NXTC0.00x

RNAZ0.00x

Debt/Assets (TTM)

NXTC0.0%

RNAZ0.0%

Interest Coverage (TTM)

NXTCN/A

RNAZN/A

Net Debt/EBITDA (TTM)

NXTC0.00x

RNAZ0.00x

Beta

NXTC1.29

RNAZ1.29

52W Performance

NXTC4.8%

RNAZ-82.4%

YTD Performance

NXTC-45.9%

RNAZ-74.9%

% from 52W High

NXTC-54.4%

RNAZ-91.1%

% from 52W Low

NXTC363.2%

RNAZ22.4%

Asset Turnover (TTM)

NXTC0.10x

RNAZ0.00x

FCF Yield (TTM)

NXTC-126.6%

RNAZ-1146.9%

Earnings Yield (TTM)

NXTC-146.3%

RNAZ-2347.6%

Dividend Yield (TTM)

NXTCN/A

RNAZN/A

Rule of 40

NXTC0.0

RNAZ0.0

EV/GP/RG

NXTCN/A

RNAZN/A

Ticker research

View NXTC research View RNAZ research

Metric	NXTC NextCure Inc	RNAZ Transcode Therapeutics Inc
Market & Valuation
Market Cap	$29M	$2M
Enterprise Value	$14M	$-6M
Price	$7.18	$1.86
P/E Ratio	N/A	N/A
P/S Ratio	0.85x	0.00x
EV/Sales	0.29x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.92x	0.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.38x	0.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-43M	$-46M
FCF (TTM)	$-37M	$-23M
EPS (TTM)	-$8.05	-$48.35
ROE (TTM)	-17546.0%	-3928.0%
ROA (TTM)	-11370.0%	-3601.0%
ROIC (TTM)	-17546.0%	-3922.0%
Financial Health
Cash	$15M	$8M
Debt	$0	$652K
Net Cash/Debt	$15M	$8M
Current Ratio (TTM)	3.47x	1.97x
Quick Ratio (TTM)	3.13x	1.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.29	1.29
52W Performance	4.8%	-82.4%
YTD Performance	-45.9%	-74.9%
% from 52W High	-54.4%	-91.1%
% from 52W Low	363.2%	22.4%
Efficiency & Yields
Asset Turnover (TTM)	0.10x	0.00x
FCF Yield (TTM)	-126.6%	-1146.9%
Earnings Yield (TTM)	-146.3%	-2347.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NXTC research	View RNAZ research